carvedilol has been researched along with Aging in 9 studies
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Beta-blockers are mainstay of current treatment of heart failure (HF)." | 6.75 | Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. ( Bettari, L; Bugatti, S; Covolo, L; Dei Cas, L; Donato, F; Gelatti, U; Giubbini, R; Lombardi, C; Metra, M; Pezzali, N; Romeo, A; Zacà, V, 2010) |
| " Demographic, physical examination and diagnostic imaging findings, blood pressure (BP), administration details and outcome were obtained from medical records of dogs receiving carvedilol for preclinical CVD." | 3.78 | Retrospective review of carvedilol administration in 38 dogs with preclinical chronic valvular heart disease. ( Boggess, MM; Gordon, SG; Hariu, CD; Miller, MW; Saunders, AB, 2012) |
| "Carvedilol, a combined beta- and alpha 1-blocking drug, was given to 8 young (age 39-47) and 21 old (age 64-79) patients with essential hypertension." | 3.68 | Pharmacokinetics of carvedilol in older and younger patients. ( Adam, W; Anderson, A; Cripps, J; Morgan, T, 1990) |
| "Beta-blockers are mainstay of current treatment of heart failure (HF)." | 2.75 | Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. ( Bettari, L; Bugatti, S; Covolo, L; Dei Cas, L; Donato, F; Gelatti, U; Giubbini, R; Lombardi, C; Metra, M; Pezzali, N; Romeo, A; Zacà, V, 2010) |
| "Heart failure is associated with increased sympathetic nervous stimulation that results in down-regulation of myocardial beta-1 receptors." | 2.42 | Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure. ( Ahmed, A, 2003) |
| "Carvedilol is a new beta-blocker antihypertensive agent with vasodilating properties secondary to alpha 1-blocking activity." | 2.40 | Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. ( Frishman, W; Moser, M, 1998) |
| "Carvedilol is an arylethanolamine that is a racemic mixture of 2 enantiomers." | 2.39 | Clinical pharmacokinetics and pharmacodynamics of carvedilol. ( Morgan, T, 1994) |
| " Chronic administration of D-galactose for a period of 6 week results into a significant increase of acetylcholine esterase enzyme level." | 1.35 | Effect of carvedilol on behavioral, mitochondrial dysfunction, and oxidative damage against D-galactose induced senescence in mice. ( Dogra, S; Kumar, A; Prakash, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bocchi, EA | 1 |
| Avila, MS | 1 |
| Ayub-Ferreira, SM | 1 |
| Kumar, A | 1 |
| Dogra, S | 1 |
| Prakash, A | 1 |
| Metra, M | 1 |
| Covolo, L | 1 |
| Pezzali, N | 1 |
| Zacà, V | 1 |
| Bugatti, S | 1 |
| Lombardi, C | 1 |
| Bettari, L | 1 |
| Romeo, A | 1 |
| Gelatti, U | 1 |
| Giubbini, R | 1 |
| Donato, F | 1 |
| Dei Cas, L | 1 |
| Gordon, SG | 1 |
| Saunders, AB | 1 |
| Hariu, CD | 1 |
| Boggess, MM | 1 |
| Miller, MW | 1 |
| Dekleva, M | 1 |
| Düngen, HD | 1 |
| Gelbrich, G | 1 |
| Incrot, S | 1 |
| Suzic Lazic, J | 1 |
| Pavlovic Kleut, M | 1 |
| Tahirovic, E | 1 |
| Waagstein, F | 1 |
| Ahmed, A | 1 |
| Morgan, T | 2 |
| Moser, M | 1 |
| Frishman, W | 1 |
| Anderson, A | 1 |
| Cripps, J | 1 |
| Adam, W | 1 |
3 reviews available for carvedilol and Aging
| Article | Year |
|---|---|
Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure.
Topics: Adrenergic beta-Antagonists; Aging; Carbazoles; Carvedilol; Down-Regulation; Heart Failure; Hemodyna | 2003 |
Clinical pharmacokinetics and pharmacodynamics of carvedilol.
Topics: Absorption; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aging; Antihypertensive | 1994 |
Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients.
Topics: Adrenergic beta-Antagonists; Aging; Antioxidants; Blood Pressure; Carbazoles; Carvedilol; Humans; Hy | 1998 |
2 trials available for carvedilol and Aging
| Article | Year |
|---|---|
Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aging; Blood Pressure; Carbazoles; Carvedilol; Female; Gen | 2010 |
Beta blockers therapy is associated with improved left ventricular systolic function and sustained exercise capacity in elderly patients with heart failure. CIBIS-ELD sub-study.
Topics: Adrenergic beta-Antagonists; Aged; Aging; Bisoprolol; Blood Pressure; Carbazoles; Carvedilol; Exerci | 2012 |
4 other studies available for carvedilol and Aging
| Article | Year |
|---|---|
Aging, cardiotoxicity, and chemotherapy.
Topics: Adrenergic beta-Antagonists; Aging; Antineoplastic Agents; Carvedilol; Heart Diseases; Humans; Risk | 2019 |
Effect of carvedilol on behavioral, mitochondrial dysfunction, and oxidative damage against D-galactose induced senescence in mice.
Topics: Acetylcholinesterase; Adrenergic beta-Antagonists; Aging; Animals; Behavior, Animal; Carbazoles; Car | 2009 |
Retrospective review of carvedilol administration in 38 dogs with preclinical chronic valvular heart disease.
Topics: Adrenergic beta-Antagonists; Aging; Animals; Carbazoles; Carvedilol; Chronic Disease; Dog Diseases; | 2012 |
Pharmacokinetics of carvedilol in older and younger patients.
Topics: Adult; Aged; Aging; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Dose-Response R | 1990 |